Skip to main content

Table 2 The expression of Nek2B with chemotherapy sensitivity of TNBC patients

From: Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin

 

PR

SD

PD

χ2

P value

Nek2B

   

13.388

0.003a

 Negative

6 (50.0%)

4 (33.3%)

2 (16.7%)

  

 Positive

8 (26.7%)

6 (20.0%)

16 (53.3%)

  
  1. PR partial response, SD stable condition, PD disease progression; aDifference was statistically significant